Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Immune Thrombocytopenia Clinical Trial

Official title:

A Prospective, One-arm and Open Clinical Study to Assess Efficacy and Safety of Avatrombopag in the Treatment of Pediatric Primary Immune Thrombocytopenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06281327
• Other study ID #: TX-ITP-001
• Status: Recruiting
• Phase: Phase 2
• Start date: March 2024
• Est. completion date: December 2025

Study information

• Verified date: February 2024
• Source: Institute of Hematology & Blood Diseases Hospital, China
• Contact: Lei Zhang, MD
• Phone: +86 13502118379
• Email: zhanglei1[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.

Description:

Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. ITP is a kind of disease with increased platelet destruction and impaired platelet production caused by autoimmunity. Conventional treatment of adult ITP includes first-line glucocorticoid and immunoglobulin therapy, second line TPO and TPO receptor agonist, splenectomy and other immunosuppressive treatments (such as rituximab, vincristine, azathioprine, etc.). Eltrombopag is currently the only TPO receptor agonist with indications for pediatric immune thrombocytopenia. However, at present, the treatment response of pediatric ITP is not good, and a considerable number of patients need to switched to other TPO receptor agonist, such as avatrombopag, because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons. Therefore, the investigators designed this clinical trial to evaluate the efficacy and safety of avatrombopag in the treatment of pediatric immune thrombocytopenia in patients who who have been treated with eltrombopag before and switched to avatrobopag because of different reasons.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

• Age 6-18 years old (including both ends), male and female;
• Diagnosed with primary immune thrombocytopenia (ITP);
• Patients who had previously received eltrombopag treatment and then converted to avatrombopag treatment because of ineffectiveness (platelet count < 30×10^9/L after eltrombopag treatment, or platelet count increased less than 2 times of the basic value, or bleeding) or large platelet fluctuation or due to patient preference, economic reasons and other reasons;
• Cardiac function of the New York Society of Cardiac Function = 2;
• Understand the study procedure and voluntarily sign the informed consent.

Exclusion Criteria:

• Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
• Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases;
• Subjects who are known to be allergic to avatrombopag or any of its excipients;
• Subjects who had used rituximab within the last 3 months;
• Subjects who underwent splenectomy within the last 3 months;
• Subjects with a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements;
• Any medical history or condition that the investigator deems unsuitable for participation in the study.

Related Conditions & MeSH terms

• Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia
• Treatment

Intervention

Drug:
• Avatrombopag
After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (<30kg) or 20mg (=30kg) once daily in all participants. ps. For subjects weighing =30kg, the dose can be started from 40mg once daily if the platelet count is < 10×10^9/L or if there is severe bleeding or risk of bleeding. Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10^9/L, avatrobopag was gradually reduced. If the platelet count >250×10^9/L, avatrobopag will be stoped until the platelet count <100×10^9/L.

Locations

Country	Name	City	State
China	Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Tianjin

Sponsors (5)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital, China	Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University, Tianjin Children's Hospital, Tianjin Medical University Second Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall efficacy response after AVA treatment within 12 weeks	Overall response rate defined as proportion of subjects with a platelet count = 30 × 10^9/L and at least 2-fold from baseline without bleeding at the meanwhile within 12 weeks after initial administration in absence of rescue therapy.	12 weeks
Secondary	Treatment response-1	Number of participants achieving a platelet count = 50×10^9/L at week 1,2,4,6,8,12 in absence of rescue therapy.	12 weeks
Secondary	Treatment response-2	Number of participants achieving a platelet count = 100×10^9/L at week 1,2,4,6,8,12 in absence of rescue therapy.	12 weeks
Secondary	Time to Response	The time required from the start of treatment to the first time a subject's platelet count was greater than or equal to 30×10^9/L and at least a two-fold increase from the baseline platelet count without bleeding in absence of rescue therapy.	12 weeks
Secondary	Persistent response	Persistent response defined as proportion of subjects with a platelet count = 30 × 10^9/L and at least 2-fold from baseline without bleeding for 4 consecutive weeks or more within 12 weeks after initial administration in absence of rescue therapy.	12 weeks
Secondary	Emergency treatment	The proportion of subjects receiving emergency treatment	12 weeks
Secondary	Reduction of concomitant drug	Percentage of patients with reduced doses of concomitant drugs at baseline	12 weeks
Secondary	Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale.	The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.	12 weeks
Secondary	Number of participants with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP.	The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (=100 total) and/or =5 small bruises (=3 cm in diameter), no mucosal bleeding;Grade 2 (mild) Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm in diameter), no mucosal bleeding;Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle;Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb>2 g/dL or suspected internal hemorrhage;	12 weeks
Secondary	Health-related quality of life survey of subjects(HRQoL)-1	In all participants ,use ITP-PAQ (ITP Patient Assessment Questionnaire) to assess the HRQoL before and after treatment.	12 weeks
Secondary	Health-related quality of life survey of subjects(HRQoL)-2	In all participants ,use FACIT-F(functional assessment of chronic illness therapy- fatigue)to assess the HRQoL before and after treatment.	12 weeks
Secondary	Health-related quality of life survey of subjects(HRQoL)-3	In all participants ,use Kids' ITP tool KIT?to assess the HRQoL before and after treatment.	12 weeks
Secondary	Health-related quality of life survey of subjects(HRQoL)-4	In all participants ,use Pediatric Quality of Life Inventory PedsQL to assess the HRQoL before and after treatment.	12 weeks